Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreren
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Oxurion NV
  6. Nieuws
  7. Andere talen
    OXUR   BE0003846632

OXURION NV

(OXUR)
  Rapport
Real Time Euronext Bruxelles  -  17:35:09 21-03-2023
0.0120 EUR    0.00%
08:04Brussel vermoedelijk hoger van start
AM
07:47Oxurion geeft krap 3 miljoen euro aan obligaties uit
AM
15/03Kleine vertraging bij Oxurion
AM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Nieuws in andere talen op OXURION NV
00:19Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas..
00:18Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas..
15/03Oxurion NV Announces Board Changes
15/03Oxurion NV Provides Update on Recruitment for Kalahari Phase 2, Part B Trial of Novel P..
14/03Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal..
14/03Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal..
09/03Oxurion Receives Transparency Notification from Negma Group
09/03Oxurion Receives Transparency Notification from Negma Group
02/03Oxurion Receives Transparency Notification from Negma Group
02/03Oxurion Receives Transparency Notification from Negma Group
02/03Funding Program between Oxurion and Negma Ends
02/03Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To Ä2..
02/03Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To Ä2..
02/03Funding Program between Oxurion and Negma Ends
02/03Oxurion NV announced that it expects to receive €20.8 million in funding
02/03Oxurion NV announced that it has received €15 million in funding from Negma Group ..
24/02Oxurion Receives Transparency Notifications from Negma Group
24/02Oxurion Receives Transparency Notifications from Negma Group
17/02Oxurion Receives Transparency Notifications from Negma Group
17/02Oxurion Receives Transparency Notifications from Negma Group
10/02Oxurion Receives Transparency Notifications
10/02Oxurion Receives Transparency Notifications
03/02Oxurion Receives Transparency Notifications from Negma Group
03/02Oxurion Receives Transparency Notifications from Negma Group
30/01Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Progr..
27/01Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Progr..
27/01Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Progr..
25/01Oxurion Announces Second Amendment to Negma Funding Program
2022Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macula..
2022Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macula..
2022Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Mac..
2022Oxurion Further Improves THR-149 Patent Position
2022Oxurion Further Improves THR-149 Patent Position
2022Oxurion Announces Interim Analysis for KALAHARI Trial
2022Oxurion Announces Interim Analysis for KALAHARI Trial
2022Oxurion NV Announces Interim Analysis for KALAHARI Trial
2022Oxurion Receives Transparency Notifications Based on New Denominator
2022Oxurion Receives Transparency Notifications Based on New Denominator
2022Oxurion : Supplement to the Prospectus of 30 August 2022
2022Oxurion Receives Transparency Notification from Fidelity Management & Research Company ..
2022Oxurion Receives Transparency Notification from Fidelity Management & Research Company ..
2022Oxurion To Participate in Upcoming Investor Conferences
2022Oxurion To Participate in Upcoming Investor Conferences
2022Oxurion To Participate in Upcoming Scientific and Investor Conferences
2022Oxurion To Participate in Upcoming Scientific and Investor Conferences
2022Oxurion Publishes First Half 2022 Results
2022Oxurion Publishes First Half 2022 Results
2022Oxurion : Prospectus for the admission to trading on Euronext Brussels of up to 30,500,000..
2022Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2022
2022Oxurion : Special report of the Board of Directors
2022Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in ..
2022Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in ..
2022Oxurion To Present at Upcoming Scientific and Investor Conferences
2022Oxurion To Present at Upcoming Scientific and Investor Conferences
2022Oxurion : Prospectus for the admission to trading on Euronext Brussels of up to 15,651,259..
2022Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
2022Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
2022Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
2022Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
2022Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
2022Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
2022Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
2022Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
2022Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022
2022Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting
2022Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting
2022Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting
2022Oxurion to Participate in Upcoming Investor Conferences
2022Oxurion to Participate in Upcoming Investor Conferences
2022Oxurion Announces Results of the Extraordinary Shareholders' Meeting held on 24 May 202..
2022Oxurion Announces Results of the Extraordinary Shareholders' Meeting held on 24 May 202..
2022Oxurion Announces Results of the Extraordinary Shareholders' Meeting held on 24 May 202..
2022Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022
2022Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022
2022Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022
2022Oxurion Announces Results of the Extraordinary and Annual Shareholders' Meetings of 3 M..
2022Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR..
2022Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR..
2022Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR..
2022Oxurion to Participate in Upcoming Conferences
2022Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment ..
2022Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment ..
2022Oxurion Announces Extraordinary and Annual Shareholders' Meetings
2022Oxurion Announces Extraordinary and Annual Shareholders' Meetings
2022Oxurion Publishes 2021 Annual Report
2022Oxurion : to Participate in Needham Virtual Healthcare Conference28 Mar 2022
2022Oxurion to Participate in Needham Virtual Healthcare Conference
2022Oxurion to Participate in Needham Virtual Healthcare Conference
2022Oxurion NV Auditor Raises 'Going Concern' Doubt
2022Oxurion Publishes 2021 Annual Report
2022Oxurion : Publishes 2021 Annual Report25 Mar 2022
2022Oxurion : Receives Transparency Notifications from Fidelity Management & Research Company ..
2022Oxurion Receives Transparency Notifications from Fidelity Management & Research Company..
2022Oxurion Successfully Closes EUR >10 Million in Private Placement; Led by new top-tier h..
2022Oxurion Successfully Closes EUR >10 Million in Private Placement
2022Oxurion NV announced that it has received €10.405496 million in funding from Fidel..
2022Oxurion successfully raises eur >10 million from leading us and european healthcare inv..
2022Oxurion successfully raises eur >10 million from leading us and european healthcare in..
2022Oxurion NV announces 2021 Full Year Results and 2022 Outlook
2022Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2021
Volgende evenement op OXURION NV